Make your prediction
Buy inPayout
$100
$181
Buy prediction

About

If the FDA's decision on Ivonescimab by Summit Therapeutics in 2026 is a full approval or an accelerated approval, the market resolves to Yes. This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued. Ivonescimab (also called AK112 or SMT112) is a bispecific antibody — think of it as a single engineered drug molecule that carries two different "hooks" instead of one, allowing it to grab and block two disease-promoting proteins at the same time. It was developed by Akeso and is being commercialized outside China by Summit Therapeutics. By simultaneously neutralizing both targets, ivonescimab is designed to slow cancer growth more effectively than drugs that block only one pathway at a time. This market and these products have not been endorsed by any aforementioned brands or its affiliates. Any references to the brand, or any associated marks are descriptive only and do not indicate an endorsement of this product or any affiliation between the brand or its affiliates and Kalshi.

If the FDA's decision on Ivonescimab by Summit Therapeutics in 2026 is a full approval or an accelerated approval, the market resolves to Yes. This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued. Ivonescimab (also called AK112 or SMT112) is a bispecific antibody — think of it as a single engineered drug molecule that carries two different "hooks" instead of one, allowing it to grab and block two disease-promoting proteins at the same time. It was developed by Akeso and is being commercialized outside China by Summit Therapeutics. By simultaneously neutralizing both targets, ivonescimab is designed to slow cancer growth more effectively than drugs that block only one pathway at a time. This market and these products have not been endorsed by any aforementioned brands or its affiliates. Any references to the brand, or any associated marks are descriptive only and do not indicate an endorsement of this product or any affiliation between the brand or its affiliates and Kalshi.

No volume detected, be the first!

Key stats

Expiry
Jan 1, 2027(89 days)
Interest
$6,782.50
Vol (24H)
$5.28↘ 97.43%
Total
$18K
Timeline & rules

Timeline & payout

This market will close and expire when an outcome occurs. Otherwise, it closes by Jan 1, 2027, 4:59 AM GMT+0.

Trading prohibitions

The following are prohibited from trading this contract:
  • Persons who are employed by any of the Source Agencies are not permitted to trade on the Contract.
  • Persons who hold any material, non-public information on the Underlying are not permitted to trade on the Contract.
  • Members of any Data Safety Monitoring Board (DSMB), Independent Data Monitoring Committee (IDMC), clinical endpoint adjudication committee, or equivalent independent oversight body with access to unblinded data for the trial..
  • Principal investigators, sub-investigators, clinical research coordinators, and site staff at sites enrolling or treating patients in the trial, to the extent they have access to unblinded or aggregated efficacy or safety data.
  • Employees, contractors, and consultants of contract research organizations (CROs), central laboratories, biostatistical firms, and data-management vendors engaged by the manufacturer to conduct, analyze, or monitor the trial.
  • Officers, directors, employees, and review staff of the FDA, EMA, PMDA, or other regulatory authority with access to non-public submissions, review documents, or communications relating to the trial or to the drug.
  • Members of institutional review boards (IRBs) or ethics committees reviewing safety or efficacy data for the trial.
  • Employees of investment banks, financial advisors, or other advisors engaged by the manufacturer or its partners with access to non-public clinical data for the trial or knowledge of the timing of its disclosure.
  • Persons who have entered into confidentiality, consulting, or expert-network agreements with the manufacturer or its agents that provide access to non-public clinical data, timelines, or results for the trial.
  • Immediate family members (spouses, domestic partners, parents, children, and siblings) and household members of any of the above.
  • Any person who has obtained material non-public information regarding the timing, content, or outcome of the results of the trial through any means, including inadvertent disclosure, misappropriation, or breach of a confidentiality obligation.
Trending markets

A new era of Coinbase has begun

The future of money is here. Be one of the first to get access and try new features the moment they’re available.

Create an account now
FAQs

Discover more

Legal
Prediction markets are offered by Coinbase Financial Markets, a registered futures commission merchant with the Commodity Futures Trading Commission and a Member of the National Futures Association. Trading prediction contracts involve substantial risk and may result in the loss of your entire investment. Contracts pay out only if the specified event occurs. Trade only if you understand the product and believe it is appropriate for your financial situation and objectives.Certain content has been prepared by third parties not affiliated with Coinbase Financial Markets or any of its affiliates and Coinbase is not responsible for such content. Coinbase is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Information is provided for informational purposes only and is not investment advice. This is not a recommendation to buy or sell a particular digital asset or to employ a particular investment strategy. Coinbase makes no representation on the accuracy, suitability, or validity of any information provided or for a particular asset. Prices shown are for illustrative purposes only. Actual cryptocurrency prices and associated stats may vary. Data presented may reflect assets traded on Coinbase’s exchange and select other cryptocurrency exchanges. Past performance is not a reliable indicator of future results.